Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Balixafortide TFA (POL6326 TFA) | 1051366-32-5 | 99.9% | 1978.16 | 25 MG
Balixafortide TFA (POL6326 TFA) is a potent, selective, and well-tolerated peptidic CXCR4 antagonist with an IC50 less than 10 nM. It demonstrates significant selectivity for CXCR4, approximately 1000-fold, over various other receptors including CXCR7. This compound effectively blocks β-arrestin recruitment and calcium flux with IC50s less than 10 nM, functioning as a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent with observed anti-cancer effects.
- Potent and selective CXCR4 antagonist
- Demonstrates high selectivity over other receptors like CXCR7
- Blocks β-arrestin recruitment and calcium flux
- Functions as a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent
- Exhibits anti-cancer effects
- Optimized for favorable mouse ADME properties
TARGETMOL CHEMICALS INC CYN 154806 TFA 1MG
Also available in 5 mg, 10 mg, 25 mg, 50 mg, 100 mg and bulk. Please contact Fisher for quotes. CYN 154806 TFA is a cyclic octapeptide and an effective selective somatostatin sst2 receptor antagonist. For the recombinant sst2, sst1, sst3, sst4 and sst5 receptors, the pIC50 values are 8.58, 5.41, 6.07, 5.76 and 6.48, respectively. Purity 99.7%
TARGETMOL CHEMICALS INC MM-102 TFA 5MG
Also available in 1 mL, 1 mg, 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and bulk. Please contact Fisher for quotes. MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor with an IC50 of 2.4 nM. This compound prevents the interaction between mixed lineage leukemia 1 (MLL1) and WD Trp-Asp repeat domain 5 (WDR5), inhibiting MLL1 H3K4 histone methyltransferase (HMT) activity and down-regulating H3K4me3, which facilitates the epigenetic reprogramming of porcine somatic cell nuclear transfer embryos. Purity 99.3%
Medchemexpress LLC MS9427 TFA | 98.4% | 1107.50 | 25 MG
MS9427 TFA is a potent PROTAC EGFR degrader that selectively degrades mutant EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. It inhibits the proliferation of NSCLC cells and can be used for anticancer research. MS9427 TFA has antiproliferative activity against HCC-827 cells, potently inducing EGFRDel19 degradation and inhibiting EGFR phosphorylation.
- Potent PROTAC EGFR degrader
- Selectively degrades mutant EGFR
- Functions through ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways
- Inhibits proliferation of NSCLC cells
- Supports anticancer research
- Displays antiproliferative activity against HCC-827 cells
- Induces EGFRDel19 degradation
- Inhibits EGFR phosphorylation
Medchemexpress LLC Pam3CSK4 (TFA) | 112208-01-2 | 99.9% | 1852.30 | 25 MG
Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist, demonstrating an EC50 of 0.47 ng/mL for human TLR1/2. This compound is a TLR1/2 heterodimer that specifically recognizes triacylated lipopeptides. It has been shown to enhance the antibacterial functions of granulocyte macrophage-colony stimulating factor (GM-CSF) induced neutrophils against Methicillin-resistant Staphylococcus aureus (MRSA).
- Acts as a TLR1/2 agonist
- Effective at an EC50 of 0.47 ng/mL for human TLR1/2
- Recognizes triacylated lipopeptides
- Enhances antibacterial functions of GM-CSF induced neutrophils
- For research use only
- Appears as a white to off-white solid
Medchemexpress LLC Pep42 TFA | 99.6% | 1335.59 | 1 MG
Pep42 TFA is a cyclic peptide ligand of GPR78. It internalizes selectively into highly metastatic human melanoma cells through a receptor-mediated process. This product is for research use only and not sold to patients.
- Cyclic peptide ligand of GPR78
- Selectively internalizes into highly metastatic human melanoma cells
Medchemexpress LLC NH2-UAMC1110 TFA | 2990021-73-1 | C23H24F5N5O5 | 5 MG
NH2-UAMC1110 TFA | 2990021-73-1 | C23H24F5N5O5 | 5 MG
Medchemexpress LLC WDR5-IN-4 TFA | 2749300-35-2 | 98.0% | 612.40 | 1 ML
WDR5-IN-4 TFA (Compound C6) is an inhibitor of the WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5), with a Kd of 0.1 nM. It displaces WDR5 from chromatin and decreases the expression of associated genes, leading to translational inhibition and nucleolar stress. This compound also exhibits anti-cancer activity.
- Inhibits the proliferation of MLL1-rearranged cancer cells MV4:11 and K562 cells with GI50s of 3.20 μM and 25.4 μM respectively, when treated with 0-50 μM for 3 days.
- Arrests the cell cycle of MV4:11 at the sub-G1 phase and induces apoptosis in MV4:11 when treated with 2 μM for 6 days.
- Promotes Hox genes in hindbrains of Rnf220+/- mice at late embryonic stages with an intrauterine injection of 100 μg (single dose).
Medchemexpress LLC Adrixetinib TFA | C27H25F6N5O7 | 25 MG
Adrixetinib TFA is an Axl/Mer/CSF1R inhibitor. This product is supplied as an off-white to light yellow solid, with a purity of 99.82% as determined by HPLC.
- Axl/Mer/CSF1R inhibitor
- High purity (99.82% by HPLC)
- Off-white to light yellow solid appearance
Medchemexpress LLC MC-VC-PAB-NH2 TFA | 1616727-21-9 | MFCD00935992 | 99.9% | 772.77 | C33H47F3N8O10 | 5 MG
MC-VC-PAB-NH2 TFA is a cleavable antibody-drug conjugate (ADC) linker used to attach cytotoxic payloads to antibodies and enable intracellular release through enzymatic cleavage. It contains a valine-citrulline dipeptide and a para-aminobenzyl self-immolative spacer and is supplied as the trifluoroacetate salt for stability in research applications.
- Cleavable valine-citrulline linker for cathepsin-mediated payload release.
- Para-aminobenzyl self-immolative spacer to facilitate efficient drug release.
- Supplied as a trifluoroacetate salt for improved stability and handling.
- High purity suitable for research use.
- Soluble in DMSO at high concentration; ultrasonic assistance may be required.
- Store sealed, away from moisture and light; follow recommended low-temperature storage for solutions.
Medchemexpress LLC Gln-AMS (TFA) | 99.9% | 588.47 | 25 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor that inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM. It is provided as a solid, white to off-white in appearance, and is stable under recommended storage conditions, making it suitable for laboratory research in metabolic enzyme, protease, anti-infection, and bacterial studies.
- Inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Available in various quantities for research needs.
- Stable under recommended storage conditions.
- Suitable for in vitro and in vivo dissolution protocols.
Medchemexpress LLC Pyridostatin (TFA) | 1472611-44-1 | 1037658 | C33H33F3N8O7 | 25 MG
Pyridostatin TFA is a G-quadruplex DNA stabilizing agent with a Kd of 490 nM, targeting both DNA and RNA G4s within cells. This selective small molecule promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage and affects proto-oncogene Src.
- Targets DNA and RNA G4s in cells
- Promotes growth arrest in human cancer cells
- Induces replication- and transcription-dependent DNA damage
- Reduces SRC protein levels and cellular motility in breast cancer cells
- Causes neurite retraction, synaptic loss, and dose-dependent neuronal death in cultured primary neurons
- Induces DNA DSBs in cultured primary neurons
- Downregulates BRCA1 protein at the transcriptional level
- High purity: 99.17%
- Solid, white to off-white appearance